DOCKET NO: ISPH-0593 PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Previously Presented): A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human short heterodimer partner-1 (SEQ ID NO: 3), wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding short heterodimer partner-1.

Claim 2(Original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3(Cancelled).

Claim 4(Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5(Original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6(Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7(Original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8(Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9(Original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10(Original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11(Previously Presented): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding human short heterodimer partner-1 (SEQ ID NO: 3).

Claim 12(Original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13(Original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14(Original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15(Currently Amended): A method of inhibiting the expression of short heterodimer partner-1 in cells or tissues comprising contacting said cells or tissues *in* ~~vivo~~ *vitro* with the compound of claim 1 so that expression of short heterodimer partner-1 is inhibited.

Claims 16-20 (Cancelled).